Q1 2023

Filed Aug 2, 2023 · 10-Q · 124 days after period end · 0001640334-23-001422

Q1 2023 · 10-Q

Revenue

$0.00

−100.0% vs Q1 2022

Net Income

-$4.00M

N/M vs Q1 2022

EPS Diluted

-$0.07

no prior Q1 2022 on file

Gross Profit$0−100.0%

Operating Income

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	$0.00	$298.50K	$99.50K	$687.96K
Net Income	-$4.00M	-$3.93M	-$59.49K	$81.12K
EPS Diluted	-$0.07	—	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR